Current and future options for lipid-lowering therapy beyond statins

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3072-3073

  Gouni Berthold, Ioanna ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; IMPLITAPIDE; LOMITAPIDE; MITOCHONDRIAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 ANTIBODY; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHOLESTEROL METABOLISM; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG EFFECT; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS;

EID: 84878655863     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170015     Document Type: Editorial

References (9)

1. Gerber PA, Gouni-Berthold I, Berneis K. Omega-3 fatty acids: role on metabolism and cardiovascular disease. Curr Pharm Des 2013; 19(17): 3074-93.
2. Gouni-Berthold I, Berthold HK. The role of niacin in lipid-lowering treatment: are we aiming too high? Curr Pharm Des 2013; 19(17): 3094-106.
3. Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013; 19(17): 3107-14.
4. Tziomalos K, Karagiannis A, Mikhailidis DP, et al. Colesevelam: a new and improved bile acid sequestrant? Curr Pharm Des 2013; 19(17): 3115-23.
5. Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013; 19(17): 3124-31.
6. Gebhard C, Huard G, Kritikou EA, et al. Apolipoprotein B antisense inhibition-update on Mipomersen. Curr Pharm Des 2013; 19(17): 3132-42.
7. Bochem AE, Kuivenhoven JA, Stroes ESG. Cholesteryl ester transfer protein (CETP) inhibitors and the treament of cardiovascular disease. Curr Pharm Des 2013; 19(17): 3143-9.
8. Kostapanos MS, Rizos EC, Papanas N, et al. Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias. Curr Pharm Des 2013; 19(17): 3150-60.
9. Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des 2013; 19(17): 3161-72.